Telix Pharmaceuticals Ltd — Director's Dealing 2022

Jan 30, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Andreas Kluge
Date of last notice	15 November 2017 (Appendix 3X)

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect Interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Gnosis Verwaltungsgesellschaft m.b.H
Date of change	27 January 2022
No. of securities held prior to change	24,675,000 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired
Number disposed	2,000,000

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$7.70 Concurrent with the Placement announced 24 January 2022, Telix co-founders, Dr Christian Behrenbruch and Dr Andreas Kluge each agreed to sell 2 million shares representing 8.1% of their respective shareholdings in Telix. The Sell- Down occurred at the same price at which New Shares are being issued under the Placement and SPP, being $7.70.
No. of securities held after change	22,675,000 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The Sell-Down reflects the first sale of shares by Dr Behrenbruch or Dr Kluge since the Company’s inception in December 2015.

Part 2 – Change of director’s interests in contracts – NOT APPLICABLE

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	19 January 2022

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3